{"protocolSection": {"identificationModule": {"nctId": "NCT02406248", "orgStudyIdInfo": {"id": "D5130C00103"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Brilinta Taiwan Post Approval Safety Study", "officialTitle": "A Multicenter, Single Arm, Open Label, Phase IV Study to Evaluate Safety and to Describe the Cumulative Incidence of Major Cardiovascular Events of Ticagrelor in Taiwanese Patients With Non ST-segment Elevation Myocardial Infarction"}, "statusModule": {"statusVerifiedDate": "2018-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-04-23", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-02-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-02-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-03-19", "studyFirstSubmitQcDate": "2015-03-30", "studyFirstPostDateStruct": {"date": "2015-04-02", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-02-08", "resultsFirstSubmitQcDate": "2018-10-12", "resultsFirstPostDateStruct": {"date": "2018-10-15", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-10-12", "lastUpdatePostDateStruct": {"date": "2018-10-15", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "A multicenter, single arm, open label, Phase IV study to evaluate safety and to describe the cumulative incidence of major cardiovascular events of Ticagrelor in Taiwanese patients with non ST-segment (a segment in the eletrocardiogram which presents the period when ventricles are depolarized) elevation myocardial infarction", "detailedDescription": "This study will be conducted in approximately 8 investigational centres in Taiwan. It is expected that approximately 100 patients will be enrolled into study treatment. This study is to describe the safety and tolerability of ticagrelor, by assessment of the bleeding events and other serious adverse events (SAEs) during 1year follow up in Taiwanese non ST-elevation myocardial infarction (NSTEMI) patients."}, "conditionsModule": {"conditions": ["Non ST-elevation Myocardial Infarction"], "keywords": ["NSTEMI"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 108, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "single arm", "type": "EXPERIMENTAL", "description": "Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)", "interventionNames": ["Drug: Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)"]}], "interventions": [{"type": "DRUG", "name": "Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)", "description": "Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)", "armGroupLabels": ["single arm"], "otherNames": ["\"Brilinta\""]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Fatal/Life-threatening Bleedings", "description": "Evaluation of PLATO (PLATelet inhibition and patient Outcomes)-defined fatal/life-threatening bleedings", "timeFrame": "during 1year follow up with ticagrelor treatment"}, {"measure": "Number of Participants With Bleeding Events (Major Bleedings)", "description": "Evaluation of PLATO (PLATelet inhibition and patient Outcomes)-defined major bleedings", "timeFrame": "during 1year follow up with ticagrelor treatment"}, {"measure": "Number of Participants With Bleeding Events (Major and Minor Bleedings)", "description": "Evaluation of PLATO (PLATelet inhibition and patient Outcomes)-defined major + minor bleedings", "timeFrame": "during 1year follow up with ticagrelor treatment"}, {"measure": "Number of Participants With Other Serious Adverse Event (SAEs)", "description": "Evaluation of serious adverse events other than bleedings", "timeFrame": "during 1year follow up with ticagrelor treatment"}, {"measure": "Number of Participants With Major Cardiovascular Events", "description": "Evaluation of major cardiovascular events including cardiovascular death, myocardial infarction or stroke", "timeFrame": "during 1year follow up with ticagrelor treatment"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Provision of informed consent prior to any study specific procedures\n2. Female or male aged at least 20 years\n3. Patient who is considered as ethnic Taiwanese\n4. Index event of non-ST elevation myocardial infarction\n\nExclusion Criteria:\n\n1. Contraindication or other reason that ticagrelor should not be administered\n2. Index event is an acute complication of Percutaneous coronary intervention (PCI)\n3. Patient has planned for an urgent coronary artery bypass graft (CABG) within 7 days from the enrolment\n4. Oral anticoagulation therapy within 30 days prior to enrolment or cannot be stopped\n5. Fibrinolytic therapy in the 24 hours prior to enrolment, or planned fibrinolytic treatment following enrolment", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Chun-peng Liu, Ph.D", "affiliation": "Kaohsiung Veterans General Hospital.", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Changhua City", "zip": "50006", "country": "Taiwan", "geoPoint": {"lat": 24.07327, "lon": 120.56276}}, {"facility": "Research Site", "city": "Hsinchu", "zip": "300", "country": "Taiwan", "geoPoint": {"lat": 24.80361, "lon": 120.96861}}, {"facility": "Research Site", "city": "Kaohsiung", "zip": "80756", "country": "Taiwan", "geoPoint": {"lat": 22.61626, "lon": 120.31333}}, {"facility": "Research Site", "city": "Kaohsiung", "zip": "81362", "country": "Taiwan", "geoPoint": {"lat": 22.61626, "lon": 120.31333}}, {"facility": "Research Site", "city": "Niao-Song-Shiang", "zip": "833", "country": "Taiwan"}, {"facility": "Research Site", "city": "Taichung", "country": "Taiwan", "geoPoint": {"lat": 24.1469, "lon": 120.6839}}, {"facility": "Research Site", "city": "Tainan County", "country": "Taiwan"}, {"facility": "Research Site", "city": "Tainan", "zip": "704", "country": "Taiwan", "geoPoint": {"lat": 22.99083, "lon": 120.21333}}, {"facility": "Research Site", "city": "Taipei", "zip": "104", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Research Site", "city": "Taipei", "zip": "11101", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Research Site", "city": "Taipei", "zip": "11217", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Research Site", "city": "Taipei", "zip": "11220", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Research Site", "city": "Taipei", "zip": "22060", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "RevisedCSP2D5130C00103Redacted_a", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=2611&filename=RevisedCSP2D5130C00103Redacted_a.pdf"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Out of the patients who provided informed consent 95.6 % (n=108) of the patients received study drug. 8 patients provided informed consent but did not fulfill eligibility criteria, out of whom 5 did not receive treatment and 3 received treatment.", "recruitmentDetails": "This study was conducted at 13 centres in Taiwan. The first patient was enrolled on 23 April 2015 and the last visit of the last patient took was on 9 February 2017. Informed consent was received for 113 patients", "groups": [{"id": "FG000", "title": "Single Arm", "description": "Ticagrelor 90mg twice daily (bd)"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "108"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "99"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "7"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Single Arm", "description": "Ticagrelor 90mg twice daily (bd)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "108"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "61.7", "spread": "12.12"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "22"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "86"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Asian", "measurements": [{"groupId": "BG000", "value": "108"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Not hispanic or latino", "measurements": [{"groupId": "BG000", "value": "108"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Fatal/Life-threatening Bleedings", "description": "Evaluation of PLATO (PLATelet inhibition and patient Outcomes)-defined fatal/life-threatening bleedings", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "during 1year follow up with ticagrelor treatment", "groups": [{"id": "OG000", "title": "Single Arm", "description": "Ticagrelor 90mg twice daily (bd)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}]}], "classes": [{"categories": [{"title": "Fatal/life-threatening bledings", "measurements": [{"groupId": "OG000", "value": "4"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With Bleeding Events (Major Bleedings)", "description": "Evaluation of PLATO (PLATelet inhibition and patient Outcomes)-defined major bleedings", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "during 1year follow up with ticagrelor treatment", "groups": [{"id": "OG000", "title": "Single Arm", "description": "Ticagrelor 90mg twice daily (bd)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}]}], "classes": [{"categories": [{"title": "Major bleedings", "measurements": [{"groupId": "OG000", "value": "7"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With Bleeding Events (Major and Minor Bleedings)", "description": "Evaluation of PLATO (PLATelet inhibition and patient Outcomes)-defined major + minor bleedings", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "during 1year follow up with ticagrelor treatment", "groups": [{"id": "OG000", "title": "Single Arm", "description": "Ticagrelor 90mg twice daily (bd)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}]}], "classes": [{"categories": [{"title": "Major and minor bleedings", "measurements": [{"groupId": "OG000", "value": "20"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With Other Serious Adverse Event (SAEs)", "description": "Evaluation of serious adverse events other than bleedings", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "during 1year follow up with ticagrelor treatment", "groups": [{"id": "OG000", "title": "Single Arm", "description": "Ticagrelor 90mg twice daily (bd)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}]}], "classes": [{"categories": [{"title": "Serious adverse events other than bleeding", "measurements": [{"groupId": "OG000", "value": "21"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With Major Cardiovascular Events", "description": "Evaluation of major cardiovascular events including cardiovascular death, myocardial infarction or stroke", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "during 1year follow up with ticagrelor treatment", "groups": [{"id": "OG000", "title": "Single Arm", "description": "Ticagrelor 90mg twice daily (bd)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}]}], "classes": [{"categories": [{"title": "Composite of major cardiovascular events", "measurements": [{"groupId": "OG000", "value": "6"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "On or after the date of first dose and up to and including 7 days following the date of last dose of study medication. 1year if the participant completed treatment according to the study plan. All-cause mortality is collected during 1 year follow-up, including deaths that occur more than 7 days after last dose.", "eventGroups": [{"id": "EG000", "title": "Single Arm", "description": "Ticagrelor 90mg twice daily (bd)", "deathsNumAffected": 7, "deathsNumAtRisk": 108, "seriousNumAffected": 23, "seriousNumAtRisk": 108, "otherNumAffected": 45, "otherNumAtRisk": 108}], "seriousEvents": [{"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 108}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}, {"term": "Hepatocellular carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}, {"term": "Haemorrhagic transformation stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}, {"term": "Glaucoma", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 108}]}, {"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}, {"term": "Cardiogenic shock", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}, {"term": "Pericardial effusion", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}, {"term": "Lymphorrhoea", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}, {"term": "Acute pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}, {"term": "Pleural effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}, {"term": "Gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}, {"term": "Catheter site haematoma", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}, {"term": "Sudden death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}, {"term": "Vascular stent restenosis", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}, {"term": "Procedural haemorrhage", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}, {"term": "Subdural haemorrhage", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}, {"term": "Tendon injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 108}]}], "otherEvents": [{"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 108}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 7, "numAtRisk": 108}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 10, "numAtRisk": 108}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 108}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 10, "numAtRisk": 108}]}, {"term": "Ecchymosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 10, "numAtRisk": 108}]}, {"term": "Hyperuricaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 108}]}, {"term": "Hypokalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 108}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 108}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA version 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 108}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Brilinta Global Clinical Lead", "organization": "AstraZeneca R&D", "email": "kontakt@astrazeneca.com", "phone": "+46 31 776 10 00"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2015-06-22", "uploadDate": "2018-02-08T07:56", "filename": "Prot_SAP_000.pdf", "size": 710914}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000009203", "term": "Myocardial Infarction"}, {"id": "D000072658", "term": "Non-ST Elevated Myocardial Infarction"}, {"id": "D000007238", "term": "Infarction"}], "ancestors": [{"id": "D000007511", "term": "Ischemia"}, {"id": "D000010335", "term": "Pathologic Processes"}, {"id": "D000009336", "term": "Necrosis"}, {"id": "D000017202", "term": "Myocardial Ischemia"}, {"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000014652", "term": "Vascular Diseases"}], "browseLeaves": [{"id": "M12155", "name": "Myocardial Infarction", "asFound": "Myocardial Infarction", "relevance": "HIGH"}, {"id": "M10282", "name": "Infarction", "asFound": "Infarction", "relevance": "HIGH"}, {"id": "M1073", "name": "Non-ST Elevated Myocardial Infarction", "asFound": "Non-ST Elevation Myocardial Infarction", "relevance": "HIGH"}, {"id": "M10543", "name": "Ischemia", "relevance": "LOW"}, {"id": "M12284", "name": "Necrosis", "relevance": "LOW"}, {"id": "M6546", "name": "Coronary Artery Disease", "relevance": "LOW"}, {"id": "M19506", "name": "Myocardial Ischemia", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077486", "term": "Ticagrelor"}], "ancestors": [{"id": "D000010975", "term": "Platelet Aggregation Inhibitors"}, {"id": "D000058921", "term": "Purinergic P2Y Receptor Antagonists"}, {"id": "D000058919", "term": "Purinergic P2 Receptor Antagonists"}, {"id": "D000058914", "term": "Purinergic Antagonists"}, {"id": "D000058905", "term": "Purinergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M1812", "name": "Ticagrelor", "asFound": "Immediate", "relevance": "HIGH"}, {"id": "M13865", "name": "Platelet Aggregation Inhibitors", "relevance": "LOW"}, {"id": "M29294", "name": "Purinergic P2Y Receptor Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "PlAggInh", "name": "Platelet Aggregation Inhibitors"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}